Mineralys Therapeutics, Inc. IPO Research Information

Mineralys Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Mineralys Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Mineralys Therapeutics, Inc.	MLYS - NASDAQ	$14.00-$16.00	$16.00	$21.10	12 million	2/10/2023
Underwriter(s): BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse, Wells Fargo
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2023-01-18 Terms Added 2023-02-02

Mineralys Therapeutics, Inc. Quote & Chart - Click for current quote - MLYS

About Mineralys Therapeutics, Inc. (adapted from Mineralys Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "MLYS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.